Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METASTRON vs SODIUM IODIDE I 123
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
FDA-approved for relief of bone pain in patients with painful osteoblastic skeletal metastases,Off-label: Treatment of pain from multiple myeloma with bone involvement
Diagnostic aid in thyroid function studies, including evaluation of thyroid uptake and imaging,Detection and localization of thyroid abnormalities (e.g., nodules, hyperthyroidism, metastatic thyroid cancer)
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 m Ci) as a single injection.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Contraindicated in patients with severely impaired renal function (e GFR < 30 m L/min). For GFR 30-50 m L/min, consider dose reduction to 1-2 m Ci; for GFR > 50 m L/min, no adjustment needed.
No specific dose adjustment recommended; however, because of renal elimination, caution in severe impairment. GFR <30 m L/min: consider reduced administered activity.
None.
FDA Pregnancy Category X. Metastron (strontium-89 chloride) is contraindicated in pregnancy due to radiation exposure. Fetal risk is highest in first trimester with potential for teratogenesis, growth retardation, and carcinogenesis. In second and third trimesters, risk of fetal damage remains significant, including possible neonatal myelosuppression. Use only if benefit outweighs risk in life-threatening maternal cancer.
Radioactive iodine crosses the placenta. Fetal thyroid begins concentrating iodine at 10-12 weeks gestation. I-123 exposure carries risk of fetal thyroid ablation and hypothyroidism, especially after first trimester. Risk is dose-dependent; diagnostic activities used in imaging (e.g., 200-400 μCi) considered lower risk but should be avoided in pregnancy unless benefit clearly outweighs risk.
Monitor for bone marrow suppression, especially thrombocytopenia and leukopenia, with regular CBCs. Use with caution in patients with impaired renal function as strontium-89 is excreted renally. Efficacy may take 7-14 days for pain relief. Avoid concurrent use with calcium products as they may compete for absorption.
Sodium iodide I-123 is a diagnostic radiopharmaceutical used for thyroid imaging, including evaluation of thyroid nodules and detection of ectopic thyroid tissue. The typical adult dose is 200-400 µCi orally. Thyroid uptake peaks at 6-24 hours post-administration. Imaging should be performed 4-6 hours after dose for early evaluation and 24 hours for delayed views. In patients with low thyroid uptake, consider interfering substances such as iodine-containing contrast media, amiodarone, or thyroid medications. Use in pregnancy only if benefit justifies risk; breastfeeding should be interrupted for at least 48 hours post-dose.
No interactions on record
No interactions on record
METASTRON and SODIUM IODIDE I 123 are distinct pharmacological agents. METASTRON belongs to the Radiopharmaceutical class and is primarily used for FDA-approved for relief of bone pain in patients with painful osteoblastic skeletal metastasesOff-label: Treatment of pain from multiple myeloma with bone involvement. SODIUM IODIDE I 123 belongs to the Radiopharmaceutical class and is primarily used for Diagnostic aid in thyroid function studies, including evaluation of thyroid uptake and imagingDetection and localization of thyroid abnormalities (e.g., nodules, hyperthyroidism, metastatic thyroid cancer). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. METASTRON carries a safety status of Category C, whereas SODIUM IODIDE I 123 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Strontium-89 chloride is not metabolized; it is excreted primarily via the kidneys. The retained fraction is incorporated into the bone matrix with a biological half-life of about 50 days.
Iodide I 123 is not metabolized; it is excreted primarily unchanged in urine, with small amounts in feces, sweat, and saliva.
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Strontium-89 does not bind to plasma proteins.
Negligible (<5%); not significantly bound to serum proteins.
Initial volume of distribution approximates extracellular fluid volume (~0.3 L/kg). Ultimate distribution includes extensive bone uptake, with a functional Vd exceeding several hundred L due to long-term retention.
0.2-0.4 L/kg; distributes to thyroid and extracellular fluid, not RBCs.
100% (intravenous administration only).
Oral: ~95% absorption; IV: 100%.
No specific dosing adjustments based on Child-Pugh class; use caution in severe hepatic impairment due to lack of data.
No specific dose adjustment recommended for Child-Pugh classification.
Safety and efficacy in pediatric patients have not been established; use is not recommended.
Neonates: 2-4 μCi/kg (0.074-0.148 MBq/kg) for uptake study; Infants/Children: 4-8 μCi/kg (0.148-0.296 MBq/kg) for uptake study; dose not to exceed adult dose.
No specific dose adjustment in elderly; monitor renal function and adjust dose as per renal guidelines since renal function may decline with age.
No specific dose adjustment; consider age-related renal function decline and use lowest effective activity.
None
Avoid calcium-rich foods and supplements for at least 2 hours before and after strontium-89 administration, as calcium may reduce its absorption. No other known dietary restrictions.
Avoid foods high in iodine such as iodized salt, seafood (fish, shellfish), seaweed, kelp, dairy products, and processed foods containing iodine. Also avoid iodine-containing supplements and multivitamins. Thyroid medications (levothyroxine, methimazole, PTU) and amiodarone should be withheld as per protocol, typically 1-2 weeks before administration.
Strontium-89 is excreted in human milk; M/P ratio not established. Due to radionuclide properties, breastfeeding is contraindicated during therapy and for at least 12 months after administration to avoid infant radiation exposure.
I-123 is excreted into breast milk. M/P ratio not established. Radioactivity in milk can be significant; breastfeeding should be interrupted and milk discarded for a period determined by radiation safety guidelines (typically 2-4 weeks post-administration for I-123).
No specific dosing adjustments for pregnancy exist due to contraindication. If administered despite contraindication, reduced dose (e.g., 148 MBq vs standard 148-222 MBq) may be considered to minimize fetal exposure, but data are insufficient. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered renal clearance) could affect strontium-89 distribution and excretion; however, no formal studies exist. Use not recommended.
Pregnancy alters thyroid physiology (increased renal clearance, increased thyroid hormone binding), but no specific dose adjustment for I-123 imaging is recommended. Use the lowest dose necessary to obtain diagnostic information. Contraindicated in pregnancy unless essential; consider alternative imaging modalities.
This medication is used to treat bone pain from cancer that has spread to your bones.,You may experience a temporary flare in pain right after injection; this usually subsides within days.,Regular blood tests are required to monitor your blood cell counts.,Avoid pregnancy and breastfeeding while on this treatment.,Notify your doctor if you develop signs of infection, bleeding, or unusual bruising.
This medication is a radioactive substance used to evaluate your thyroid gland. You will swallow a capsule or liquid.,Drink plenty of water before and after the dose to help clear the radioactivity from your body.,Avoid iodine-containing foods (e.g., iodized salt, seafood, kelp) and medications (e.g., thyroid hormones, amiodarone) for at least 1-2 weeks prior to the scan, as directed.,You may resume normal activities after the scan but will be mildly radioactive for about 24 hours; maintain distance from pregnant women and infants.,Notify your doctor if you are pregnant, breastfeeding, or have a history of thyroid disease or iodine allergy.,Possible side effects include nausea, vomiting, or allergic reactions (rash, itching, swelling).